Phase 2
Completed N=100
Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
Source: ClinicalTrials.gov NCT01926977 ↗Enrolled (actual)
100
Serious AEs
0.0%
Results posted
Mar 2016
Primary outcomePrimary: Evidence of Anterior Chamber Inflammation — 1; 10; 0; 1 participants
Summary
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evidence of Anterior Chamber Inflammation |
1; 10; 0; 1 | — |
| SECONDARY Patients With Post Injection Pain Score of One or Higher on Pain Scale |
7; 9; 0; 1 | — |
Eligibility Criteria
Inclusion Criteria
- Able to provide informed consent and comply with study assessments for the full duration of the study
- Age >/= 65 years
- New onset Neovascular Age-Related Macular Degeneration or (See No.4)
- Previously treated Neovascular Age-Related Macular Degeneration with Lucentis or Eylea intravitreal injections
- Visual Acuity of 20/400 or better
- No history of Post injection pain or inflammation with prior treatments -
Exclusion Criteria
- History of Endophthalmitis in either eye
- Uncontrolled or symptomatic Dry Eye Syndrome
- History of Anterior or Posterior Uveitis
- History of Post injection pain or inflammation with prior treatments
- Recent thromboembolic event(<3 months)
- Pregnancy(positive pregnancy test) or Lactation/Premenopausal women not using adequate contraception -
Data sourced from ClinicalTrials.gov (NCT01926977). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.